New York, October 29, 2014 — MTS Health Investors, LLC (“MTS”), the New York based healthcare private equity firm, announced today that funds managed by MTS have completed an investment in Celerion Holdings, Inc. (“Celerion” or the “Company”). MTS has partnered with management to recapitalize the business and provide capital to support future growth. Terms of the transaction were not disclosed.
Celerion, with operations throughout North America, Europe and Asia, provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research. The Company serves its clients through its global network of owned facilities with a focus on applied translational medicine to support early drug development decisions..
Curtis S. Lane, Partner at MTS, said, “MTS has spent a significant amount of time evaluating the outsourced pharmaceutical services sector and believes that Celerion represents an ideal investment platform as a market-leader in early clinical research through proof of concept studies. Celerion’s leadership has built a company with a stellar reputation and a track record of providing unmatched service and rapid turnaround times to its pharmaceutical and biotechnology clients. We look forward to partnering with the Company to provide additional financial and operational resources and to pursue new opportunities for growth.”
Susan Thornton, CEO and President at Celerion, said, “We are excited to partner with MTS as we enter the next phase of our growth. With a strong scientific foundation and commitment to excellence, we have worked to create a market-leading reputation and platform with unique and diversified capabilities to meet the needs of the pharmaceutical industry. With MTS’s investment we will be provided with additional tools and resources to grow our customer base, drive value to our clients, and explore new pathways for growth.”
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion apples our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labelling of new medicines.
With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. For more information please visit www.celerion.com.
MTS Health Investors, LLC, located in New York, is a healthcare private equity firm that makes investments in operating companies within the healthcare industry. MTS targets companies that provide differentiated and cost-effective solutions in the healthcare and pharmaceutical services industry as well as low-technology manufacturing sectors of the healthcare industry. For further information, please visit www.mtshealthinvestors.com.